SALV-ENZA is among the first phase II placebo-controlled double-blinded randomized studies to test SRT in combination with a next generation anti-androgen receptor antagonist in men with contemporary high-risk recurrent prostate cancer after radical prostatectomy. The gene discussed is AR; the disease is prostate carcinoma.